Incyte Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Incyte stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View analyst ratings for Incyte or view top-rated stocks.

Wall Street analysts have given Incyte a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Incyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) released its earnings results on Tuesday, May, 4th. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.42 by $0.25. The biopharmaceutical company earned $604.72 million during the quarter, compared to analyst estimates of $657.73 million. Incyte had a trailing twelve-month return on equity of 20.10% and a net margin of 17.70%. The business's revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the business posted ($2.86) earnings per share.
View Incyte's earnings history.

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 15.1% and is now trading at $82.76.
View which stocks have been most impacted by COVID-19.

14 analysts have issued 12 month price objectives for Incyte's stock. Their forecasts range from $70.00 to $121.00. On average, they expect Incyte's stock price to reach $97.00 in the next year. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for Incyte or view top-rated stocks among Wall Street analysts.

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of INCY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (14.55%), Price T Rowe Associates Inc. MD (13.67%), BlackRock Inc. (8.04%), Capital International Investors (2.50%), Renaissance Technologies LLC (2.23%) and Geode Capital Management LLC (1.54%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Capital International Investors, Renaissance Technologies LLC, UBS Asset Management Americas Inc., Canada Pension Plan Investment Board, Nissay Asset Management Corp Japan ADV, State of Wisconsin Investment Board, and BlackRock Inc.. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte or view top insider-selling stocks.

INCY stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Camber Capital Management LP, Armistice Capital LLC, Royal Bank of Canada, Virginia Retirement Systems ET AL, Geode Capital Management LLC, Polar Capital Holdings Plc, and D. E. Shaw & Co. Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte or or view top insider-buying stocks.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INCY stock can currently be purchased for approximately $82.76.

Incyte has a market capitalization of $18.20 billion and generates $2.67 billion in revenue each year. The biopharmaceutical company earns $-295,700,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

Incyte employs 1,773 workers across the globe.

Incyte was founded in 1991.

The official website for Incyte is www.incyte.com.

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]